AstraZeneca Pharma India Secures CDSCO Nod For Enhertu Additional Breast Cancer Indication

28 July 2026

Astrazeneca Pharma India Ltd.

Received CDSCO approval for Trastuzumab Deruxtecan (Enhertu®) for neoadjuvant treatment of HER2-positive Stage II/III breast cancer, following THP therapy. Expands Enhertu's market, reinforcing oncology portfolio.